22 May 2013
Keywords: bavituximab, yields, good, response, rates, ph, ib
Article | 18 June 2007
California, USA-based Peregrine Pharmaceuticals has presented positive results from a Phase Ib trial of its oncology agent bavituximab, in
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 June 2007
21 May 2013
© 2013 thepharmaletter.com